Mak, Lung-Yi
Seto, Wai-Kay
Fung, James
Yuen, Man-Fung
Article History
Received: 28 August 2019
Accepted: 19 October 2019
First Online: 19 November 2019
Compliance with ethical standards
:
: WKS received speaker fees from Mylan; received speaker fees and is an advisory board member of AbbVie; and received speaker fees, is an advisory board member and received research funding from Gilead Sciences.; MFY serves as advisor/consultant for AbbVie, Arbutus Biopharma, Bristol Myer Squibb, Dicerna Pharmaceuticals, GlaxoSmithKline, Gilead Sciences, Janssen, Merck Sharp and Dohme, Clear B Therapeutics, Springbank Pharmaceuticals and receives Grant/research supports from Assembly Biosciences, Arrowhead Pharmaceuticals, Bristol Myer Squibb, Fujirebio Incorporation, Gilead Sciences, Merck Sharp and Dohme, Springbank Pharmaceuticals, and Sysmex Corporation. J. Fung and L. Y. Mak have no potential conflict of interest to disclose.
: This article does not contain any studies with human or animal subjects.